Crescent Biopharma (CBIO) Non-cash Items (2016 - 2025)

Crescent Biopharma (CBIO) has 10 years of Non-cash Items data on file, last reported at $426000.0 in Q1 2025.

• Non-cash Items for Q1 2025 came in at $426000.0, down 89.42% year-over-year; the trailing twelve-month figure through Mar 2025 was $426000.0 (down 89.42% YoY), and the FY2024 annual result was $1.5 million, up 11.42% from the prior year.
• Non-cash Items declined to $426000.0 in Q1 2025 per CBIO's latest filing, from $1.5 million in the prior quarter.
• Over five years, Non-cash Items peaked at $8.8 million in Q3 2024 and troughed at $2000.0 in Q1 2021.
• A 5-year average of $2.5 million and a median of $1.3 million in 2023 frame the typical range for Non-cash Items.
• The sharpest annual moves came in 2021 and 2022: Non-cash Items slumped 99.99% in 2021, then surged 104846.62% in 2022.
• A 5-year view of Non-cash Items shows it stood at $4.1 million in 2021, then slumped by 89.68% to $425104.0 in 2022, then surged by 206.75% to $1.3 million in 2023, then climbed by 11.42% to $1.5 million in 2024, then slumped by 70.68% to $426000.0 in 2025.
• Business Quant data shows CBIO's Non-cash Items at $426000.0 in Q1 2025, $1.5 million in Q4 2024, and $8.8 million in Q3 2024.